Back to today’s briefing

Story perspectives

Pharmaceutical Innovation Surges Amid Rising Development Costs

3/25/2025

39 9

Summary

Story summary

Pharmaceutical innovation is on the upswing, with a Deloitte report showing a promising internal rate of return of 5.9% in 2024, fueled by high-value drugs like GLP-1 assets. Yet, the journey is fraught with challenges, as drug development costs soar to $2.23 billion and competition for trial sites intensifies, urging a strategic rethink in R&D.

1 of 1

Story summary

Pharmaceutical innovation is on the upswing, with a Deloitte report showing a promising internal rate of return of 5.9% in 2024, fueled by high-value drugs like GLP-1 assets. Yet, the journey is fraught with challenges, as drug development costs soar to $2.23 billion and competition for trial sites intensifies, urging a strategic rethink in R&D.